Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma

Prospective, single center, randomized, open label, parallel group, 2-arm study assessing the clinical benefit in term of enhancement of overall response rate of Isatuximab in combination with CellProtect as compared to Isatuximab for the treatment of patients with newly diagnosed multiple myeloma who are eligible for stem cell transplantation (SCT) as maintenance after SCT.

Trial Details

NCT ID
NCT04558931
Phase
PHASE2
Sponsor
Karolinska Institutet
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • CellProtect
  • Isatuximab
Locations (sample)
  • Stockholm, Sweden|59.32938,18.06871

Key Eligibility Criteria

  • I1. Active multiple myeloma, as defined by the IMWG criteria.
  • I2. Evidence of measurable disease:
  • I3. Serum monoclonal (M)-protein ≥1.0 g/dL measured using serum protein immunoelectrophoresis a.and/or I4. Urine M-protein ≥200 mg/24 hours measure…
  • a. and/or I5. in patients without measurable M protein in serum or urine as per previous criteria, serum immunoglobulin free light chain (sFLC) ≥10…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →